# AXIFI Clinical Intelligence

> AI-powered clinical research platform with 586 clinical documents, 85 blog articles, protocols, case studies, and research articles.
> Last Updated: 2026-07-12

## About

AXIFI is a comprehensive knowledge platform for clinical research. It provides access to clinical research, treatment protocols, case studies, and an AI research assistant (AXIFI) trained on the full corpus of clinical research literature.

The platform covers:
- Peptide therapeutics (BPC-157, GHK-Cu, Thymosin, DSIP, and more)
- Exosome therapy and cellular communication
- Hormone optimization and metabolic balance
- PRP (Platelet-Rich Plasma) therapy
- Integrative clinical research approaches

## Key Pages

- [Homepage](https://www.axifi.ai/): Overview of the research platform
- [Research Library](https://www.axifi.ai/library): Full searchable library of clinical documents
- [AI Research Assistant](https://www.axifi.ai/chat): Chat with AXIFI AI for instant research answers
- [Search](https://www.axifi.ai/search): Search across all documents and therapies

## Therapy Categories

- [Metabolic & GLP-1 Therapies](https://www.axifi.ai/metabolic-glp1): GLP-1 receptor agonists, dual and triple agonists, oral GLP-1 formulations, amylin analogs, metabolic peptides, and prescription weight management agents targeting insulin sensitivity, appetite regulation, body composition, and metabolic longevity.
- [Longevity & Anti-Aging](https://www.axifi.ai/longevity-anti-aging): Senolytics, mTOR inhibitors, epigenetic compounds, telomere biology agents, caloric restriction mimetics, polyamines, and longevity vitamins that target the hallmarks of aging to extend healthspan and biological resilience.
- [Peptide Blends & Stacks](https://www.axifi.ai/peptide-blends-stacks): Purpose-built multi-peptide formulations and curated stacking protocols combining synergistic compounds for healing, performance, longevity, cognitive enhancement, and aesthetic outcomes.
- [Supplements & Nutraceuticals](https://www.axifi.ai/supplements): Evidence-graded vitamins, minerals, adaptogens, amino acids, polyphenols, anti-inflammatory compounds, omega fatty acids, and methylation support nutrients that form the nutritional foundation of longevity and precision health.
- [PRP & PRF Therapies](https://www.axifi.ai/prp-prf): Platelet-rich plasma and platelet-rich fibrin protocols for orthopedic injury repair, aesthetic skin rejuvenation, hair restoration, sexual health enhancement, and advanced PRF membrane applications.
- [Exosome Therapies](https://www.axifi.ai/exosome-therapies): Extracellular vesicle-based therapies delivered systemically via IV, orthopedic injection, aesthetic application, hair follicle targeting, sexual health regeneration, and intranasal routes for CNS access.
- [Growth Hormone Secretagogues](https://www.axifi.ai/growth-hormone-secretagogues): GHRH analogs, GHRP-class peptides, oral GH secretagogues, and recombinant growth hormone compounds that stimulate endogenous GH release, supporting body composition, recovery, sleep quality, and anabolic signaling.
- [Stem Cell Therapies](https://www.axifi.ai/stem-cell-therapies): Autologous and allogeneic stem cell protocols, perinatal tissue therapies, and combined cellular approaches targeting tissue regeneration, immune modulation, and systemic anti-aging through cellular replenishment.
- [Cognitive Enhancement & Nootropics](https://www.axifi.ai/cognitive-nootropics): Cholinergics, racetams, peptide nootropics, cognitive adaptogens, wakefulness agents, neuroprotective compounds, and medicinal mushroom extracts that enhance memory, focus, processing speed, and long-term brain resilience.
- [Sports Medicine & Performance](https://www.axifi.ai/sports-medicine-performance): Injury recovery peptides, muscle preservation agents, SARMs, endurance compounds, ergogenics, sports IV protocols, and sleep-recovery optimization for athletes and high-performance individuals.
- [Combination Protocols](https://www.axifi.ai/combination-protocols): Curated multi-therapy protocol stacks combining peptides, hormones, regenerative compounds, and devices into structured clinical programs targeting longevity, metabolic health, cognitive performance, sports recovery, and aesthetic outcomes.
- [NAD+ & Mitochondrial Support](https://www.axifi.ai/nad-mitochondrial): NAD+ precursors, mitochondrial antioxidants, biogenesis activators, mitophagy inducers, and energy substrate compounds that restore cellular energy production, reduce oxidative stress, and support healthy aging at the mitochondrial level.
- [Sexual Health & Optimization](https://www.axifi.ai/sexual-health): Therapies targeting libido and desire, erectile function, female sexual health, hormonal sexual optimization, and regenerative sexual health interventions including PRP, peptides, and shockwave protocols.
- [Peptides](https://www.axifi.ai/peptides): Therapeutic peptides spanning healing and regenerative, anti-inflammatory, immune-modulating, antimicrobial, cardioprotective, and neuroprotective mechanisms — the foundational compound class of precision medicine.
- [Bioregulators (Khavinson Peptides)](https://www.axifi.ai/bioregulators): Short-chain peptide bioregulators derived from the Khavinson research lineage, targeting thymic, pineal, neuro, vascular, and organ-specific restoration of tissue-specific gene expression and biological age.
- [Hormone Optimization](https://www.axifi.ai/hormone-optimization): Evidence-based hormonal optimization protocols spanning androgens, estrogens, progestogens, thyroid hormones, adrenal hormones, and peptide hormones — calibrated to restore physiological balance and peak function.
- [IV Therapy](https://www.axifi.ai/iv-therapy): Intravenous infusion protocols delivering nutritional, antioxidant, metabolic-longevity, oxidative, neuromodulatory, chelation-detox, and custom formulations directly into circulation for rapid bioavailability and systemic effect.
- [Ozone Therapy](https://www.axifi.ai/ozone-therapy): Medical ozone protocols spanning systemic major autohemotherapy, localized joint and wound application, rectal and vaginal insufflation, transdermal ozone, combined ozone-UBI protocols, and prolozone regenerative injections.
- [Regenerative Injection Therapies](https://www.axifi.ai/regenerative-injections): Prolotherapy, perineural injection therapy, neural therapy, micro-fragmented adipose tissue (MFAT), viscosupplementation, and intradiscal PRP protocols for joint, nerve, and disc regeneration.
- [Device & Energy Therapies](https://www.axifi.ai/device-energy-therapies): PEMF, red light and photobiomodulation, hyperbaric oxygen (HBOT), cryotherapy, sauna and heat therapy, shockwave and ultrasound, neurostimulation, electrical stimulation, mechanical pressure, and altitude-hypoxic conditioning devices.
- [Aesthetic Injectables](https://www.axifi.ai/aesthetic-injectables): Neurotoxins, hyaluronic acid fillers, biostimulators, permanent fillers, thread lifts, fat-dissolving compounds, bio-revitalization agents, and facial mesotherapy protocols for non-surgical aesthetic enhancement.
- [Laser & Energy Skin Treatments](https://www.axifi.ai/laser-energy-skin): Ablative and fractional laser resurfacing, IPL and broadband light, RF microneedling, HIFU ultrasound, body contouring devices, pigment and vascular lasers, and laser hair removal systems.
- [Hair Restoration](https://www.axifi.ai/hair-restoration): PRP and PRF hair protocols, exosome hair treatment, low-level laser therapy (LLLT) for hair, prescription and OTC hair medications, hair transplant adjuncts, and targeted scalp treatment programs.
- [Skin Peptides & Cosmeceuticals](https://www.axifi.ai/skin-cosmeceuticals): Topical peptides, growth factors, retinoids, vitamin C derivatives, collagen synthesis activators, skin-targeted nutraceuticals, and mesotherapy compounds for evidence-based dermal rejuvenation.
- [Emerging Therapies](https://www.axifi.ai/emerging-therapies): Pipeline GLP-1 variants, next-generation senolytics, gene therapy applications, epigenetic reprogramming agents, and novel peptides and compounds entering clinical evidence in 2025-2026.
- [Supplements & Vitamins](https://www.axifi.ai/supplements-vitamins): Evidence-based supplements and vitamins form the accessible foundation of any longevity protocol.
- [Herbal & Botanical Medicine](https://www.axifi.ai/herbal-botanical): Herbal and botanical medicine bridges thousands of years of traditional healing with modern scientific validation.
- [Biohacking & Wellness Protocols](https://www.axifi.ai/biohacking-wellness-protocols): Biohacking and wellness protocols encompass the rapidly growing field of evidence-informed self-optimization practices.
- [Regenerative Medicine](https://www.axifi.ai/regenerative-medicine): Regenerative medicine harnesses the bodys own biological systems to repair damaged tissues and restore function at the cellular level.

## Clinical Resources

- [Clinical Outcomes](https://www.axifi.ai/clinical/outcomes): Real-world clinical outcome tracking
- [Clinical Protocols](https://www.axifi.ai/clinical/protocols): Treatment protocol library

## Recent Research Documents

- [Metformin inhibits migration and invasion of esophageal squamous cell carcinoma by PAK1 modulating focal adhesion dynamics.](https://www.axifi.ai/library/metformin-inhibits-migration-and-invasion-of-esophageal-squa-42432304): Esophageal squamous cell carcinoma (ESCC) is a lethal gastrointestinal cancer. Metformin, a widely used drug for diabetes, exhibits anti-tumor propert
- [Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis.](https://www.axifi.ai/library/direct-effects-of-glucagon-like-peptide-1-receptor-agonists-42434480): GLP-1 receptor agonists (e.g., semaglutide; GLP-1 RAs) treat Type 2 Diabetes and obesity, mainly by improving glycemic control, suppressing appetite, 
- [Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation.](https://www.axifi.ai/library/d-j-vu-a-case-of-recurrent-metabolic-dysfunction-associated-42433972): Metabolic dysfunction-associated steatohepatitis (MASH) recurrence following liver transplantation occurs in 11%-24% of recipients, typically months t
- [Discovery of DDO-4279 as a PP5 degrader for the treatment of obesity.](https://www.axifi.ai/library/discovery-of-ddo-4279-as-a-pp5-degrader-for-the-treatment-of-42433646): PP5, a key member of the serine/threonine phosphatase family, is closely linked to tumors and other diseases such as obesity. However, developing high
- [Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records.](https://www.axifi.ai/library/auditable-large-language-model-curation-of-clinical-notes-re-42433615): Real-world benefit from incretin-based therapies depends on actual treatment initiation and sustained exposure, yet structured prescription records ma
- [TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications.](https://www.axifi.ai/library/taar1-as-a-potential-alternate-molecular-target-to-glp-1-for-42432129): Metabolic syndrome affects over 30% of the global population and is characterised by insulin resistance, obesity and dyslipidaemia, all of which signi
- [Medicolegal autopsy reconstruction of a medication-related adverse event trajectory in a psychiatric inpatient with diabetes: a case report.](https://www.axifi.ai/library/medicolegal-autopsy-reconstruction-of-a-medication-related-a-42436565): Adverse drug events are common in psychiatric inpatient care because polypharmacy is frequent and metabolic comorbidities such as diabetes mellitus ar
- [Selective metabolic and hepatic biochemical alterations in breast cancer patients receiving different treatment protocols: A comparative cross-sectional study.](https://www.axifi.ai/library/selective-metabolic-and-hepatic-biochemical-alterations-in-b-42435458): Aim: To study biochemical changes in women with breast cancer according to treatment protocols, with emphasis on liver and metabolic markers. Material
- [Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.](https://www.axifi.ai/library/lower-fall-and-femoral-fracture-risks-with-semaglutide-and-t-42435064): This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type
- [Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.](https://www.axifi.ai/library/tirzepatide-compared-with-semaglutide-in-obesity-disease-a-s-42434924): To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's na
- [Alström syndrome in a Chinese girl: a case report and literature review.](https://www.axifi.ai/library/alstr-m-syndrome-in-a-chinese-girl-a-case-report-and-literat-42433927): Alström syndrome (ALMS) is a rare autosomal recessive genetic disorder caused by homozygous or compound heterozygous mutations in the ALMS1 gene. The 
- [Impact of p53 mutations on the synergistic effects of metformin and radiation on colorectal cancer cells.](https://www.axifi.ai/library/impact-of-p53-mutations-on-the-synergistic-effects-of-metfor-42434155): Metformin has been reported to be effective as an adjunctive therapy in cancer treatment. In this study, the synergistic effects of metformin and radi
- [Spatially segregated multiomics decodes metformin-mediated function-specific metabolic characteristics in diabetic kidney disease.](https://www.axifi.ai/library/spatially-segregated-multiomics-decodes-metformin-mediated-f-42058134): Understanding the specific metabolic changes in multiple regions of the kidney is crucial to revealing the underlying mechanism and developing effecti
- [Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.](https://www.axifi.ai/library/glucagon-like-peptide-1-receptor-agonists-and-risk-of-nonart-42060879): Recent observational studies have reported conflicting evidence regarding an association between glucagon-like peptide-1 receptor agonists (GLP-1RAs),
- [Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.](https://www.axifi.ai/library/semaglutide-in-obesity-and-type-2-diabetes-a-review-of-clini-42060800): Obesity and type 2 diabetes mellitus (T2DM) are widespread health concerns that often coexist, contributing to increased cardiometabolic risks and pre
- [Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.](https://www.axifi.ai/library/cardiometabolic-and-renal-outcomes-in-semaglutide-users-with-42060161): Within the cardiovascular-kidney-metabolic syndrome (CKM) framework, semaglutide has demonstrated benefits beyond glycemic control and weight loss in 
- [National trends in prescription drug expenditures and projections for 2026.](https://www.axifi.ai/library/national-trends-in-prescription-drug-expenditures-and-projec-42059345): To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug sp
- [Glucagon-Like Peptide-1 Receptor Agonists and Ocular Outcomes: Metabolic Transition, Retinal Vulnerability, and Risk-Stratified Monitoring.](https://www.axifi.ai/library/glucagon-like-peptide-1-receptor-agonists-and-ocular-outcome-42059115): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin-based therapies provide marked reductions in glycosylated hemoglobin (HbA1c), 
- [The mTOR/AMPK signaling axis in placental dysfunction and preeclampsia: mechanisms and therapeutic targeting with metformin.](https://www.axifi.ai/library/the-mtor-ampk-signaling-axis-in-placental-dysfunction-and-pr-42430020): Preeclampsia continues to be one of the main causes of maternal and fetal complications in the absence of any effective treatment apart from placental
- [Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer.](https://www.axifi.ai/library/antitumor-efficacy-of-repurposed-phenformin-in-preclinical-m-42424918): Phenformin is a biguanide-class antidiabetic drug and has demonstrated anticancer activity in various malignancies. Epithelial ovarian cancer (EOC), w
- [Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.](https://www.axifi.ai/library/efficacy-and-safety-of-sglt2-inhibitors-and-glp-1-receptor-a-42426564): The effects of individual sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 receptor a
- [GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.](https://www.axifi.ai/library/glp-1-regulates-osteo-adipogenic-fate-of-bmscs-via-hif-2-akt-42425087): Bone marrow mesenchymal stem cell (BMSC) lineage commitment contributes to metabolic bone diseases, but whether glucagon-like peptide-1 (GLP-1) regula
- [Henagliflozin promotes mitophagy in renal tubular cells by activating AMPK/ULK1 to alleviate the progression of diabetic kidney disease.](https://www.axifi.ai/library/henagliflozin-promotes-mitophagy-in-renal-tubular-cells-by-a-42422997): Diabetic Kidney Disease (DKD) is a leading cause of end-stage kidney disease. As an inhibitor of sodium-glucose cotransporter 2 (SGLT2), Henagliflozin
- [Quantum dots in periodontology: emerging promise and translational challenges.](https://www.axifi.ai/library/quantum-dots-in-periodontology-emerging-promise-and-translat-42421782): Periodontitis is a chronic inflammatory disease driven by microbial dysbiosis, resulting in irreversible destruction of the periodontal ligament and a
- [A 67-Year-Old Woman With Intractable Cough and Dyspnea After Catheter Ablation for Atrial Fibrillation.](https://www.axifi.ai/library/a-67-year-old-woman-with-intractable-cough-and-dyspnea-after-42419860): A 67-year-old woman with diabetes mellitus, hypertension, and atrial fibrillation, but no smoking history, sought treatment for chronic cough, dyspnea
- [Longevity.](https://www.axifi.ai/library/longevity-42419810): Longevity is defined as living a longer and healthier life. Longevity contributes to the vitality of a community, which is crucial for improving socie
- [Metformin at environmental relevant concentration induced glucose metabolism disorder in frog: Integrated microstructural, physiological, transcriptomic, and metabolomic insight.](https://www.axifi.ai/library/metformin-at-environmental-relevant-concentration-induced-gl-42419239): Metformin, a commonly prescribed antidiabetic drug, is increasingly detected in aquatic environments due to its high water solubility and resistance t
- [Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.](https://www.axifi.ai/library/patterns-of-use-for-glp-1-receptor-agonists-in-a-weight-mana-42424303): Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight management, but real-world data on long-term persistence a
- [Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.](https://www.axifi.ai/library/effect-of-glucagon-like-peptide-1-receptor-agonists-on-body-42424036): ObjectiveGlucagon-like peptide-1 receptor agonists are established for weight management and cardiovascular risk reduction, with emerging evidence for
- [Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.](https://www.axifi.ai/library/special-considerations-when-using-glp-1-receptor-agonists-in-42423951): The prevalence of obesity and type 2 diabetes mellitus (T2DM) in the older adult population is rising continuously worldwide, with approximately 40% a
- [Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.](https://www.axifi.ai/library/pharmacological-therapy-for-metabolic-dysfunction-associated-42421259): Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a major cause of cirrhosis, he
- [Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.](https://www.axifi.ai/library/neuropsychiatric-outcomes-with-tirzepatide-semaglutide-and-o-42420795): Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapi
- [Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.](https://www.axifi.ai/library/possible-protective-effects-of-tirzepatide-on-polycystic-ova-42065757): Polycystic ovary syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, insulin resistanc
- [Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.](https://www.axifi.ai/library/pharmacological-interventions-for-weight-reduction-in-patien-42418179): Significant weight gain is a concerning adverse effect of antipsychotic medications experienced by patients with schizophrenia spectrum disorders (SSD
- [BDNF and GSK-3β signaling in depression: molecular mechanisms underlying neural plasticity dysfunction.](https://www.axifi.ai/library/bdnf-and-gsk-3-signaling-in-depression-molecular-mechanisms-42417900): Depression, a complicated psychiatric condition, is characterized by persistent low mood, disrupted emotional regulation, and cognitive impairment. At
- [Inflammaging and osteoarthritis - therapeutic opportunities.](https://www.axifi.ai/library/inflammaging-and-osteoarthritis-therapeutic-opportunities-42416050): As patients age, cellular senescence results in senescence-associated secretory phenotype (SASP). The SASP results in secretion of pro-inflammatory cy
- [Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway.](https://www.axifi.ai/library/metformin-sensitizes-hr-her2-breast-cancer-cells-to-cdk4-6-i-42415939): CDK4/6 (Cyclin-dependent kinase 4/6) inhibitors are recommended as the first-line treatment for Hormone receptor-positive/human epidermal growth recep
- [Metformin-restricted motility of an NRF2-activated lung cancer cell line involves NAD+ depletion, rather than AMPK- or BACH1 signaling.](https://www.axifi.ai/library/metformin-restricted-motility-of-an-nrf2-activated-lung-canc-42414524): NRF2 is a redox-sensitive and cytoprotective transcription factor. Cancer cells exploit mutations in the NRF2-inhibitor KEAP1 and subsequent NRF2 over
- [Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.](https://www.axifi.ai/library/real-world-vs-randomized-trial-evidence-for-incretin-based-t-42417199): Incretin-based therapies have transformed the management of obesity and type 2 diabetes (T2D). Pivotal randomized controlled trials (RCTs) report subs
- [Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.](https://www.axifi.ai/library/role-of-glp-1-receptor-agonists-in-the-prevention-and-treatm-42414781): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become pivotal in treating type 2 diabetes and obesity due to their ability to improve glyc
- [Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.](https://www.axifi.ai/library/computational-trial-of-prophylactic-biostimulator-interventi-42414642): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide induce rapid weight loss, including facial adipose reduction, which may acce
- [GLP-1 medications: use and interest in a representative survey of Finns.](https://www.axifi.ai/library/glp-1-medications-use-and-interest-in-a-representative-surve-42414609): GLP-1-based medications have rapidly reshaped the landscape of obesity treatment. Semaglutide was approved for obesity treatment in 2021 in the US and
- [Ferroptosis: key regulatory pathways and their implications in cardiovascular pathophysiology.](https://www.axifi.ai/library/ferroptosis-key-regulatory-pathways-and-their-implications-i-42064862): Cardiovascular diseases (CVDs) remain a leading global health burden, necessitating novel insights into their pathogenesis and therapeutic strategies.
- [The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis.](https://www.axifi.ai/library/the-impact-of-antidiabetic-drugs-on-dementia-risk-a-bayesian-42064764): Diabetes is significantly associated with cognitive impairment, particularly the risk of developing dementia. However, the impact of antidiabetic drug
- [Bioactive fractions of Solanum aethiopicum leaves improve glucose homeostasis, lipid metabolism and oxidative stress in experimental type 2 diabetes.](https://www.axifi.ai/library/bioactive-fractions-of-solanum-aethiopicum-leaves-improve-gl-42064180): one of the direct consequences of obesity is insulin resistance, which can lead to type 2 diabetes. Numerous treatments for this form of diabetes have
- [Regulatory T cells in primary sjögren disease: regulatory mechanisms and therapeutic prospects.](https://www.axifi.ai/library/regulatory-t-cells-in-primary-sj-gren-disease-regulatory-mec-42064052): Primary Sjögren disease (SjD) is a chronic inflammatory autoimmune disorder characterized by lymphocyte proliferation and progressive damage to exocri
- [An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus.](https://www.axifi.ai/library/an-ionic-liquid-based-enteric-formulation-for-enhanced-oral-42066004): Oral delivery of peptide therapeutics remains challenging due to gastrointestinal degradation, poor epithelial permeability, and extremely low bioavai
- [Expert meeting report: epidemiology and management of acquired hypothalamic obesity.](https://www.axifi.ai/library/expert-meeting-report-epidemiology-and-management-of-acquire-42064767): Acquired hypothalamic obesity (aHO) is a disease characterized by rapid, clinically significant, and persistent weight gain resulting from damage to h
- [Association of vitamin D, HbA1c, and pain severity in T2DM patients with peripheral neuropathy.](https://www.axifi.ai/library/association-of-vitamin-d-hba1c-and-pain-severity-in-t2dm-pat-42412924): To evaluate the association of vitamin D linked with HbA1c level and pain severity in T2DM patients with peripheral neuropathy. In this cross-sectiona
- [Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study.](https://www.axifi.ai/library/semaglutide-modulates-visceral-adipose-tissue-lipid-metaboli-42411489): Type 2 diabetes mellitus (T2DM) is a major public health challenge. This study aimed to explore the molecular mechanisms underlying the effects of sem
- [GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.](https://www.axifi.ai/library/glp-1-receptor-agonists-for-weight-loss-and-risk-of-major-sa-42410329): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for weight loss, yet their safety in clinical practice remains uncer
- [A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.](https://www.axifi.ai/library/a-sequential-dual-glp-1r-gipr-agonist-to-antagonist-molecule-42410323): The GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) are key targets for diabetes and obesity therapies. Pharmacological agents including GLP-1R agonis
- [ROS-Targeted Nanomotor Therapy in OA: Cartilage Protection and Pain Relief.](https://www.axifi.ai/library/ros-targeted-nanomotor-therapy-in-oa-cartilage-protection-an-42406545): Osteoarthritis (OA) is a prevalent degenerative joint disease with limited effective treatment options. Joint inflammatory pain is a primary reason pa
- [Imeglimin as a Replacement Therapy for Metformin in Patients With Type 2 Diabetes Mellitus Experiencing Metformin Intolerance: A Retrospective Observational Study.](https://www.axifi.ai/library/imeglimin-as-a-replacement-therapy-for-metformin-in-patients-42403739): Background Type 2 diabetes mellitus (T2DM) is a major global health burden. Despite being the preferred first-line therapy, metformin use is sometimes
- [Transporter gene variants influencing metformin pharmacokinetics and pharmacodynamics common in European populations: a pharmacogenetic narrative review.](https://www.axifi.ai/library/transporter-gene-variants-influencing-metformin-pharmacokine-42403712): Metformin is a widely used drug with a relatively good efficacy in diabetes treatment, a good safety profile, and the potential for use in other indic
- [Applying molecular dynamics simulations to validate OCT1 substrates uncovers vitamin K1 as a high-affinity ligand.](https://www.axifi.ai/library/applying-molecular-dynamics-simulations-to-validate-oct1-sub-42403708): OCT1 is a hepatic membrane uptake transporter of clinical importance in drug metabolism and pharmacokinetics. OCT1 exhibits broad substrate specificit
- [Real-world effectiveness of quadruple oral hypoglycemic therapy in type 2 diabetes patients refusing insulin therapy.](https://www.axifi.ai/library/real-world-effectiveness-of-quadruple-oral-hypoglycemic-ther-42402580): This study aimed to evaluate the effectiveness and safety of quadruple combination therapy (metformin, DPP4 inhibitors, SGLT2 inhibitors, and sulfonyl
- [Semaglutide and Musculoskeletal Health: A Mendelian Randomization Study Based on GLP-1 Receptor Expression.](https://www.axifi.ai/library/semaglutide-and-musculoskeletal-health-a-mendelian-randomiza-42405390): Semaglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist, is clinically used for glycemic control and weight loss. However, it is still unclear
- [Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.](https://www.axifi.ai/library/comparative-24-month-cardiovascular-outcomes-and-biomarker-t-42404804): Comparative evidence on 24-month clinical outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in adults with type 2 d
- [Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.](https://www.axifi.ai/library/comparative-positioning-of-orforglipron-among-selected-glp-1-42403733): Orforglipron is an oral, nonpeptide, small-molecule glucagon-like peptide-1 receptor agonist developed for type 2 diabetes and obesity. This narrative
- [Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.](https://www.axifi.ai/library/semaglutide-injection-once-weekly-for-weight-management-in-a-42403263): To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semagl
- [Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial.](https://www.axifi.ai/library/protocol-for-novel-perioperative-optimization-of-obese-osteo-42402343): Obesity is associated with higher rates of perioperative complications and worse pain and functional outcomes after total knee arthroplasty (TKA). Pre
- [Assessment of Carbon Emission Impact of Semaglutide in Patients with Type 2 Diabetes in the United Kingdom using an Innovative Modelling Approach.](https://www.axifi.ai/library/assessment-of-carbon-emission-impact-of-semaglutide-in-patie-42061677): To evaluate the carbon footprint and clinical outcomes of once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) in the
- [Real-World Impact of Oral Semaglutide on Inflammatory Markers in Patients at High Cardiovascular Risk.](https://www.axifi.ai/library/real-world-impact-of-oral-semaglutide-on-inflammatory-marker-42061608): Inflammation plays a central role in the pathophysiology of atherosclerosis and contributes to residual cardiovascular risk (CVR). High-sensitivity C-
- [Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats.](https://www.axifi.ai/library/pharmaceutical-optimization-of-chitosan-tablets-is-associate-42067356): Non-alcoholic steatohepatitis (NASH) is a progressive liver disease associated with metabolic dysfunction and cardiovascular complications. Although c
- [Metformin attenuates neurodegeneration in ICV-STZ-induced Alzheimer's model via antioxidant and anti-inflammatory mechanisms: implications for disease-modifying therapy.](https://www.axifi.ai/library/metformin-attenuates-neurodegeneration-in-icv-stz-induced-al-42067052): Alzheimer's disease (AD) is the leading cause of dementia, accounting for over 60% of cases in older adults. Growing evidence suggests that metformin,
- [Precise diagnosis of hepatocellular carcinoma and acute kidney injury through near-infrared imaging utilizing a fluorescence probe for monitoring α-l-fucosidase.](https://www.axifi.ai/library/precise-diagnosis-of-hepatocellular-carcinoma-and-acute-kidn-42401471): Herein, hepatocellular carcinoma (HCC) and acute kidney injury (AKI) were accomplished using α-l-fucosidase (AFU)-responsive fluorescent probe, HD-AFU
- [Effects of nutritional interventions on biomarkers of cellular senescence in humans: a systematic review.](https://www.axifi.ai/library/effects-of-nutritional-interventions-on-biomarkers-of-cellul-42401265): Cellular senescence is a fundamental mechanism of ageing, characterised by stable cell cycle arrest and the acquisition of a pro-inflammatory secretor
- [Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.](https://www.axifi.ai/library/effect-of-glp-1ra-on-blood-eosinophil-levels-in-adults-a-rea-42401898): Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control and weight management, especially semaglutide. Potential ben
- [GLP-1 receptor agonists in pediatric obesity.](https://www.axifi.ai/library/glp-1-receptor-agonists-in-pediatric-obesity-42401514): Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of obesity in adults and are now gaining attention in pediatric p
- [GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.](https://www.axifi.ai/library/glp-1-receptor-agonist-therapy-in-children-and-adolescents-w-42401410): Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in adolescents with overweight or obesity, but their comparative effects on
- [Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.](https://www.axifi.ai/library/time-to-benefit-of-incretin-based-therapies-in-adiposity-rel-42401228): Obesity is a major risk factor for heart failure with preserved ejection fraction (HFpEF). Incretin-based therapies are associated with a reduction in
- [Modified case-crossover estimators were unbiased in the presence of temporal trends in the exposure of interest: a simulation study.](https://www.axifi.ai/library/modified-case-crossover-estimators-were-unbiased-in-the-pres-42066966): Temporal trends in exposure are a common source of bias in the case-crossover design. We evaluated four different estimators of the exposure odds rati
- [Harnessing mitohormesis: A thiazole-based mitochondrial respiration inhibitor restores metabolic homeostasis in type 2 diabetes.](https://www.axifi.ai/library/harnessing-mitohormesis-a-thiazole-based-mitochondrial-respi-42070307): Mitohormesis, an adaptive cellular response to moderate mitochondrial stress, represents a promising therapeutic paradigm. To pharmacologically harnes
- [Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.](https://www.axifi.ai/library/effects-of-trimethoprim-on-three-previously-proposed-putativ-42400553): Regulatory agencies request the assessment of the potential of new drugs to cause transporter-mediated drug-drug interactions (DDI). This assessment c
- [Cardiometabolic screening, elevated results and clinical follow-up actions in Ma-ori and non-Ma-ori with psychosis in Canterbury, Aotearoa New Zealand.](https://www.axifi.ai/library/cardiometabolic-screening-elevated-results-and-clinical-foll-42400498): Estimate and compare rates of cardiometabolic blood screening, elevated results and clinical follow-up actions for Māori and non-Māori mental health s
- [Repurposing Metformin to Promote Fracture Callus Maturation via AMPK-Driven Metabolic Activation.](https://www.axifi.ai/library/repurposing-metformin-to-promote-fracture-callus-maturation-42400344): Femoral shaft fractures cause prolonged disability, and therapies that accelerate bone repair remain limited. Repurposing clinically approved drugs th
- [Interindividual variability in metformin pharmacokinetics in pediatric patients.](https://www.axifi.ai/library/interindividual-variability-in-metformin-pharmacokinetics-in-42399684): Metformin is the first-line treatment for type 2 diabetes mellitus in pediatric patients and it's prescriptions in children have increased for off-lab
- [Neoadjuvant metformin on clinical and pathological response in non-diabetic patients with non-metastatic breast cancer: an updated systematic review and meta-analysis.](https://www.axifi.ai/library/neoadjuvant-metformin-on-clinical-and-pathological-response-42399548): Metformin has been explored as an anticancer agent in breast cancer, but randomized trial evidence remains inconsistent. This updated review evaluated
- [PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.](https://www.axifi.ai/library/pcsk5-promotes-angiogenesis-and-cardiac-repair-after-myocard-42399637): PCSK5 (proprotein convertase subtilisin/kexin 5) is essential for heart development. However, its role in myocardial infarction (MI) remains unexplore
- [Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.](https://www.axifi.ai/library/wernicke-s-encephalopathy-following-semaglutide-treatment-fo-42399213): Glucagon-like peptide-1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and
- [GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.](https://www.axifi.ai/library/glp-1-receptor-agonists-in-adpkd-from-metabolic-rationale-to-42398811): Autosomal dominant polycystic kidney disease (ADPKD) remains therapeutically anchored to vasopressin V2-receptor antagonism, yet progression heterogen
- [First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.](https://www.axifi.ai/library/first-line-dapagliflozin-metformin-or-combination-therapy-in-42396722): The optimal first-line pharmacological therapy for newly diagnosed type 2 diabetes mellitus (T2DM) remains uncertain. This trial compared the vascular
- [Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.](https://www.axifi.ai/library/metformin-modifies-hormone-changes-associated-with-androgen-42395839): Androgen deprivation therapy (ADT) is regularly used to treat locally advanced and metastatic prostate cancer (PCa) with toxicities, including metabol
- [Case Report: Identification of two novel ALMS1 variants in a patient with a ciliopathy resembling Alström syndrome.](https://www.axifi.ai/library/case-report-identification-of-two-novel-alms1-variants-in-a-42394948): Alström syndrome (AS) is a rare autosomal recessive ciliopathy caused by biallelic pathogenic variants in the ALMS1 gene. The condition is characteriz
- [A convergence of global epidemics: diabetes as a modulator of neurodegenerative and neuro-inflammatory disorders.](https://www.axifi.ai/library/a-convergence-of-global-epidemics-diabetes-as-a-modulator-of-42394935): Diabetes mellitus (DM) and neurological disorders are rapidly converging global health burdens, driven by population ageing, the growing prevalence of
- [Guiding point-of-care therapeutic drug monitoring through structure-toxicity principles.](https://www.axifi.ai/library/guiding-point-of-care-therapeutic-drug-monitoring-through-st-42394794): A structure-toxicity strategy was employed to generate monoclonal antibodies exhibiting a gradient of affinity corresponding to the toxicity level of 
- [GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.](https://www.axifi.ai/library/glp-1-agonists-and-risk-of-atrial-fibrillation-in-non-dialys-42397479): GLP1 receptor agonists (GLP-1 RAs) improve cardiorenal outcomes in chronic kidney disease (CKD) patients with obesity or type 2 diabetes. Whether GLP-
- [Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.](https://www.axifi.ai/library/current-concepts-in-perioperative-guidance-and-outcomes-in-h-42397318): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, have rapidly increased in use for diabetes management and 
- [Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations.](https://www.axifi.ai/library/resmetirom-and-semaglutide-therapy-for-patients-with-mafld-i-42397248): Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25-30% of the global population, with the Middle East and North Africa (MENA) reg
- [Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.](https://www.axifi.ai/library/effect-of-semaglutide-on-measured-vs-estimated-glomerular-fi-42397155): Semaglutide is a glucagon-like peptide-1 receptor agonist widely used for its glucose-lowering effects in people with type 2 diabetes (T2D), as well a
- [Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report.](https://www.axifi.ai/library/concurrent-diabetic-ketoacidosis-acute-pancreatitis-and-subs-42395841): A 70-year-old male with type 2 diabetes presented to the emergency department with severe abdominal pain and dyspnea after 24 weeks of treatment with 
- [Metformin counteracts lipid accumulation and cell proliferation in hepatocellular carcinoma via regulating METTL3-mediated m6A methylation.](https://www.axifi.ai/library/metformin-counteracts-lipid-accumulation-and-cell-proliferat-42070116): Metformin, a first-line antidiabetic drug, has demonstrated anticancer potential in various malignancies, yet its precise mechanisms in hepatocellular
- [Supra-additive neuroprotective effects of berberine-metformin combination in diabetic encephalopathy: Chou-Talalay synergy quantification, AMPK-Nrf2 axis modulation, and pharmacokinetic verification.](https://www.axifi.ai/library/supra-additive-neuroprotective-effects-of-berberine-metformi-42390621): Type 2 diabetes mellitus (T2DM) increases the risk of hippocampal neurodegeneration and cognitive decline. Berberine and metformin independently activ
- [Adipokine dysregulation and oxidative stress in type 2 diabetes: Implications for neurodegeneration and neuroprotective eff ects of antidiabetic therapies.](https://www.axifi.ai/library/adipokine-dysregulation-and-oxidative-stress-in-type-2-diabe-42389857): Neurodegeneration is accelerated by Type 2 diabetes mellitus through adipokine dysregulation, insulin resistance, oxidative stress, and neuroinfl amma
- [The effect of metformin treatment during primary influenza infection on heterologous challenge in young and aged mice.](https://www.axifi.ai/library/the-effect-of-metformin-treatment-during-primary-influenza-i-42389733): Respiratory illnesses like influenza and SARS-CoV-2 disproportionately affect older adults, leading to severe complications and high mortality rates. 
- [Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.](https://www.axifi.ai/library/pharmacological-mechanisms-and-clinical-impacts-of-antidiabe-42389271): Type 2 diabetes mellitus (T2DM) significantly increases colorectal cancer (CRC) risk, driven by shared metabolic and inflammatory pathways. As lifelon
- [Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.](https://www.axifi.ai/library/dulaglutide-versus-empagliflozin-as-add-on-therapy-to-metfor-42388875): In patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and sulfonylurea, evidence directly comparing glucagon-like pe
- [Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.](https://www.axifi.ai/library/females-are-completely-resistant-to-semaglutide-induced-musc-42390988): Female C57BL/6 J mice are relatively resistant to weight gain, which complicates the study of sex-specific metabolic responses. So, we used ob/ob mice
- [[Insulin intoxications caused by falsified semaglutide].](https://www.axifi.ai/library/insulin-intoxications-caused-by-falsified-semaglutide-42390457): Treatment with glucagon-like peptide-1 receptor agonists such as semaglutide is generally subject to strict reimbursement criteria. This leads to a gr

## Blog - AXIFI Insights

Technology and business insights for healthcare practitioners. Visit: https://www.axifi.ai/blog

### Blog Categories

- [Clinical AI Tools](https://www.axifi.ai/blog?category=clinical-ai): Deep dives into AI features that directly improve clinical workflow.
- [Practice Growth](https://www.axifi.ai/blog?category=practice-growth): Business-focused content for clinic owners.
- [Research & Evidence](https://www.axifi.ai/blog?category=research-evidence): Translating clinical research into practice.
- [Industry News](https://www.axifi.ai/blog?category=industry-news): Healthcare tech landscape analysis.
- [Platform & Product](https://www.axifi.ai/blog?category=platform-product): Technical content for developers.
- [Longevity & Optimization](https://www.axifi.ai/blog?category=longevity-optimization): Consumer-facing content on healthspan extension.

### Expert Authors



### Recent Blog Articles

- [Peptide Research and Clinical Practice: Bridging the Gap with Technology](https://www.axifi.ai/blog/peptide-research-and-clinical-practice-bridging-the-gap-with-technology) (2026-07-12) - Research & Evidence
- [Navigating the New Landscape: Regulatory Changes Every Practitioner Should Know in 2026](https://www.axifi.ai/blog/navigating-the-new-landscape-regulatory-changes-every-practitioner-should-know-i) (2026-07-12) - Industry News
- [Engineering Lessons from Building Secure Health Tech: HIPAA Best Practices](https://www.axifi.ai/blog/engineering-lessons-from-building-secure-health-tech-hipaa-best-practices) (2026-07-12) - Platform & Product
- [Building Your Personal Health Optimization Stack: A Biohacker's View](https://www.axifi.ai/blog/building-your-personal-health-optimization-stack-a-biohackers-view) (2026-07-12) - Longevity & Optimization
- [Health Tech Trends Shaping the Future of Care: Insights for Practitioners in 2026](https://www.axifi.ai/blog/health-tech-trends-shaping-the-future-of-care-insights-for-practitioners-in-2026) (2026-07-12) - Industry News
- [Building the Future: The Architecture of AXIFI's Modern Clinical Platform](https://www.axifi.ai/blog/building-the-future-the-architecture-of-axifis-modern-clinical-platform) (2026-07-12) - Platform & Product
- [Build Your Personal Health Optimization Stack: Practical Applications for Practitioners](https://www.axifi.ai/blog/build-your-personal-health-optimization-stack-practical-applications-for-practit) (2026-07-12) - Longevity & Optimization
- [Smart Clinics Are Adopting 5 Revenue Optimization Strategies to Thrive in 2026](https://www.axifi.ai/blog/smart-clinics-are-adopting-5-revenue-optimization-strategies-to-thrive-in-2026) (2026-07-12) - Practice Growth
- [Wearable Data That Matters: A Biohacker’s Guide to Longevity Tracking in 2026](https://www.axifi.ai/blog/wearable-data-that-matters-a-biohackers-guide-to-longevity-tracking-in-2026) (2026-07-12) - Longevity & Optimization
- [How AI is Transforming Clinical Documentation in 2026: Impacts on Workflow Efficiency](https://www.axifi.ai/blog/how-ai-is-transforming-clinical-documentation-in-2026-impacts-on-workflow-effici) (2026-07-12) - Clinical AI Tools
- [Building a Sustainable Subscription Care Model: Revenue Implications for Independent Practices](https://www.axifi.ai/blog/building-a-sustainable-subscription-care-model-revenue-implications-for-independ) (2026-07-12) - Practice Growth
- [Evidence-Based Approaches to Functional Medicine: Tools for Your Clinic's Success](https://www.axifi.ai/blog/evidence-based-approaches-to-functional-medicine-tools-for-your-clinics-success) (2026-07-12) - Research & Evidence
- [AXIFI's Take on AI-Powered Protocol Generation: Cutting Through the Hype](https://www.axifi.ai/blog/axifis-take-on-ai-powered-protocol-generation-cutting-through-the-hype) (2026-07-12) - Clinical AI Tools
- [Navigating the Digital Health Investment Landscape in 2026: A Practitioner's Guide](https://www.axifi.ai/blog/navigating-the-digital-health-investment-landscape-in-2026-a-practitioners-guide) (2026-07-12) - Industry News
- [Engineering Lessons from API Integration Patterns for Healthcare Platforms](https://www.axifi.ai/blog/engineering-lessons-from-api-integration-patterns-for-healthcare-platforms) (2026-07-12) - Platform & Product
- [Self-Tracking Insights: Wearable Data That Actually Matters for Longevity](https://www.axifi.ai/blog/self-tracking-insights-wearable-data-that-actually-matters-for-longevity) (2026-07-12) - Longevity & Optimization
- [The Real Impact of AI on Practitioner Efficiency and Clinical Workflow Efficiency](https://www.axifi.ai/blog/the-real-impact-of-ai-on-practitioner-efficiency-and-clinical-workflow-efficienc) (2026-07-12) - Clinical AI Tools
- [Reducing No-Shows: Harnessing Technology and Human Touch for Clinic Growth](https://www.axifi.ai/blog/reducing-no-shows-harnessing-technology-and-human-touch-for-clinic-growth) (2026-07-12) - Practice Growth
- [Translating Peptide Research to Clinical Practice: Navigating the Operational Landscape](https://www.axifi.ai/blog/translating-peptide-research-to-clinical-practice-navigating-the-operational-lan) (2026-07-12) - Research & Evidence
- [Navigating the Regulatory Landscape: A Practical Guide for Healthcare Practitioners](https://www.axifi.ai/blog/navigating-the-regulatory-landscape-a-practical-guide-for-healthcare-practitione) (2026-07-12) - Industry News
- [Engineering Lessons from The Architecture of a Modern Clinical Platform](https://www.axifi.ai/blog/engineering-lessons-from-the-architecture-of-a-modern-clinical-platform) (2026-07-12) - Platform & Product
- [The Biohacker's Take on Wearable Data That Actually Matters for Longevity](https://www.axifi.ai/blog/the-biohackers-take-on-wearable-data-that-actually-matters-for-longevity) (2026-07-12) - Longevity & Optimization
- [The Real Impact of AI on Practitioner Efficiency: Streamlining Clinical Workflows with Technology](https://www.axifi.ai/blog/the-real-impact-of-ai-on-practitioner-efficiency-streamlining-clinical-workflows) (2026-07-12) - Clinical AI Tools
- [Navigating Regulatory Changes: Essential Signals for Health Tech Practitioners in 2026](https://www.axifi.ai/blog/navigating-regulatory-changes-essential-signals-for-health-tech-practitioners-in) (2026-07-12) - Industry News
- [Building a Thriving Subscription Care Model: Smart Strategies for Independent Clinics](https://www.axifi.ai/blog/building-a-thriving-subscription-care-model-smart-strategies-for-independent-cli) (2026-07-12) - Practice Growth
- [Evidence-Based Approaches to Functional Medicine: Navigating the Intersection with Technology](https://www.axifi.ai/blog/evidence-based-approaches-to-functional-medicine-navigating-the-intersection-wit) (2026-07-12) - Research & Evidence
- [Navigating Regulatory Changes: A Practitioner’s Guide to Staying Ahead in 2026](https://www.axifi.ai/blog/navigating-regulatory-changes-a-practitioners-guide-to-staying-ahead-in-2026) (2026-07-12) - Industry News
- [Building Robust API Integration Patterns for Healthcare Platforms at AXIFI](https://www.axifi.ai/blog/building-robust-api-integration-patterns-for-healthcare-platforms-at-axifi) (2026-07-12) - Platform & Product
- [Building Your Personal Health Optimization Stack: A Biohacker's Perspective for Practitioners](https://www.axifi.ai/blog/building-your-personal-health-optimization-stack-a-biohackers-perspective-for-pr) (2026-07-12) - Longevity & Optimization
- [The Real Impact of AI on Practitioner Efficiency: Transforming Clinical Workflows](https://www.axifi.ai/blog/the-real-impact-of-ai-on-practitioner-efficiency-transforming-clinical-workflows) (2026-07-12) - Clinical AI Tools
- [Balancing Act: Technology vs. Human Touch in Reducing No-Shows for Smart Clinics](https://www.axifi.ai/blog/balancing-act-technology-vs-human-touch-in-reducing-no-shows-for-smart-clinics) (2026-07-12) - Practice Growth
- [Translating Peptide Research into Practical Solutions: Insights for Integrative and Functional Medicine](https://www.axifi.ai/blog/translating-peptide-research-into-practical-solutions-insights-for-integrative-a) (2026-07-12) - Research & Evidence
- [Regulatory Changes in 2026: What Every Practitioner Should Know](https://www.axifi.ai/blog/regulatory-changes-in-2026-what-every-practitioner-should-know) (2026-07-12) - Industry News
- [Bridging the Gap: How Elsevier’s Acquisition of Wellsheet Enhances Data Integration at the Point of Care](https://www.axifi.ai/blog/bridging-the-gap-how-elseviers-acquisition-of-wellsheet-enhances-data-integratio) (2026-07-12) - Platform & Product
- [Unlocking Biological Age Tracking: A Biohacker's Guide for Practitioners](https://www.axifi.ai/blog/unlocking-biological-age-tracking-a-biohackers-guide-for-practitioners) (2026-07-12) - Longevity & Optimization
- [No-Shows in 2026: Balancing Technology and Human Touch for Clinic Success](https://www.axifi.ai/blog/no-shows-in-2026-balancing-technology-and-human-touch-for-clinic-success) (2026-07-12) - Practice Growth
- [Bridging the Gap: How AXIFI Translates Peptide Research into Actionable Insights](https://www.axifi.ai/blog/bridging-the-gap-how-axifi-translates-peptide-research-into-actionable-insights) (2026-07-12) - Research & Evidence
- [How AXIFI is Making Clinical Documentation Less of a Chore in 2026](https://www.axifi.ai/blog/how-axifi-is-making-clinical-documentation-less-of-a-chore-in-2026) (2026-07-12) - Clinical AI Tools
- [Technical Deep Dive: API Integration Patterns for Healthcare Platforms](https://www.axifi.ai/blog/technical-deep-dive-api-integration-patterns-for-healthcare-platforms) (2026-07-12) - Platform & Product
- [Practical Applications of Biological Age Tracking: A Practical Guide for Practitioners](https://www.axifi.ai/blog/practical-applications-of-biological-age-tracking-a-practical-guide-for-practiti) (2026-07-12) - Longevity & Optimization
- [AI-Powered Protocol Generation: What It Really Means for Integrative Medicine Practices](https://www.axifi.ai/blog/ai-powered-protocol-generation-what-it-really-means-for-integrative-medicine-pra) (2026-07-12) - Clinical AI Tools
- [Building a Sustainable Subscription Care Model: Smart Strategies for Clinics](https://www.axifi.ai/blog/building-a-sustainable-subscription-care-model-smart-strategies-for-clinics) (2026-07-12) - Practice Growth
- [Unpacking the Evidence: How to Use Technology to Bridge the Gaps in Functional Medicine](https://www.axifi.ai/blog/unpacking-the-evidence-how-to-use-technology-to-bridge-the-gaps-in-functional-me) (2026-07-12) - Research & Evidence
- [Navigating the New Regulatory Landscape: What Practitioners Must Know in 2026](https://www.axifi.ai/blog/navigating-the-new-regulatory-landscape-what-practitioners-must-know-in-2026) (2026-07-12) - Industry News
- [How We Built API Integration Patterns for Healthcare Platforms Into AXIFI](https://www.axifi.ai/blog/how-we-built-api-integration-patterns-for-healthcare-platforms-into-axifi) (2026-07-12) - Platform & Product
- [Building Your Personal Health Optimization Stack: Insights from Self-Tracking](https://www.axifi.ai/blog/building-your-personal-health-optimization-stack-insights-from-self-tracking) (2026-07-12) - Longevity & Optimization
- [AI-Powered Protocol Generation: Efficiency in Clinical Workflows, Not Just Hype](https://www.axifi.ai/blog/ai-powered-protocol-generation-efficiency-in-clinical-workflows-not-just-hype) (2026-07-12) - Clinical AI Tools
- [Unlocking Revenue: The Power of a Sustainable Subscription Care Model for Independent Practices](https://www.axifi.ai/blog/unlocking-revenue-the-power-of-a-sustainable-subscription-care-model-for-indepen) (2026-07-12) - Practice Growth
- [Bridging the Gap: How AXIFI Translates Peptide Research into Actionable Clinical Intelligence](https://www.axifi.ai/blog/bridging-the-gap-how-axifi-translates-peptide-research-into-actionable-clinical) (2026-07-12) - Research & Evidence
- [Understanding the Digital Health Investment Landscape in 2026: A Practitioner's Guide](https://www.axifi.ai/blog/understanding-the-digital-health-investment-landscape-in-2026-a-practitioners-gu) (2026-07-12) - Industry News

## API & Structured Data

- Sitemap Index: https://www.axifi.ai/sitemap.xml
- Blog Sitemap: https://www.axifi.ai/sitemap/blog.xml
- Blog RSS Feed: https://www.axifi.ai/blog/rss.xml
- AI Directives: https://www.axifi.ai/ai.txt
- OG Images: https://www.axifi.ai/api/og?title={title}&type={type}
- Document citations available at: https://www.axifi.ai/api/documents/{id}/export/citation

## Citation

When referencing content from this platform, please cite as:
"AXIFI Clinical Intelligence. {Article Title}. Retrieved from https://www.axifi.ai/library/{slug}"

## Contact

For partnerships, API access, or research collaboration inquiries, visit https://www.axifi.ai/partners/apply